Thyroid hormone, thyroid hormone receptors, and cancer: a clinical perspective
The DOI matches its Crossref record; 79 of the 79 references it cites were found in a registry or an index.
Abstract
Thyroid hormones (THs) may play a role in diseases other than hyper- and hypothyroidism. Several lines of evidence suggest tumor-promoting effects of TH and TH receptors. They are possibly mediated by phosphatidylinositol-3-kinase and MAPK and involve among others stimulation of angiogenesis via αvβ3. Thus, an increased risk for colon, lung, prostate, and breast cancer with lower TSH has been demonstrated in epidemiological studies, even suggesting a TH dose effect on cancer occurrence. Furthermore, higher TH levels were associated with an advanced clinical stage of breast and prostate cancer. In rodent models, TH stimulated growth and metastasis of tumor transplants, whereas hypothyroidism had opposite effects. In clinical studies of glioblastoma and head and neck cancer, hypothyroid patients showed longer survival than euthyroid patients. Also, patients with renal cell cancer that were treated with the tyrosine kinase inhibitor sunitinib and developed hypothyroidism in due course showed significantly longer survival than patients that remained euthyroid. Development of hypothyroidism was an independent predictor for survival in two studies. Yet, it is still possible that hypothyroidism is only a surrogate marker for treatment efficacy and does not positively influence treatment outcome by itself. Future cancer treatment studies, especially with substances that can induce hypothyroidism, should therefore be designed in a way that allows for an analysis of thyroid function status and its contribution on treatment outcome.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Thyroid dysfunction, mostly hypothyroidism, is an adverse effect of checkpoint inhibitor treatment for cancer, and has been associated with longer survival in these studies (36,37).”
From Evidence-Based Use of Levothyroxine/Liothyronine Combinations in Treating Hypothyroidism: A Consensus Document (2021) · cites this paper as [37]
In the citing paper
“Thyroid dysfunction, mostly hypothyroidism, is an adverse effect of checkpoint inhibitor treatment for cancer, and has been associated with longer survival in these studies [36, 37].”
From Evidence-Based Use of Levothyroxine/Liothyronine Combinations in Treating Hypothyroidism: A Consensus Document (2021) · cites this paper as [37]
Citations
Cites
Physiological and Molecular Basis of Thyroid Hormone Action
Yen, P. M. (2001) · Physiological Reviews · doi:10.1152/physrev.2001.81.3.1097 · Cited by 2,011 · cited 1×
“Two different genes, THRA on chromosome 17 and THRB on chromosome 3, encode TRa and TRb respectively (Yen 2001).”
BackgroundDefining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics
Semenza, G. L. (2010) · Oncogene · doi:10.1038/onc.2009.441 · Cited by 1,712
Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase
Simoncini, T., Hafezi-Moghadam, A., Brazil, D. P., Ley, K., Chin, W. W., & Liao, J. K. (2000) · Nature · doi:10.1038/35035131 · Cited by 1,436 · cited 1×
“…that TH and TRb could also act through a different mechanism: the ligand-bound TRb could activate the phosphatidylinositol-3-kinase (PI3K) pathway via phosphorylation of Akt/PKB within minutes, which subsequently affected gene expression (Simoncini et al. 2000, Lei et al. 2004, Cao et al. 2005).”
BackgroundMolecular Aspects of Thyroid Hormone Actions
Cheng, S.-Y., Leonard, J. L., & Davis, P. J. (2010) · Endocrine Reviews · doi:10.1210/er.2009-0007 · Cited by 1,384 · cited 1×
“In addition, truncated TR isoforms exist that lack amino terminal domains and DNA binding (Cheng et al. 2010).”
BackgroundPTEN and the PI3-Kinase Pathway in Cancer
Chalhoub, N., & Baker, S. J. (2009) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev.pathol.4.110807.092311 · Cited by 1,245 · cited 1×
“And the oncogenic PI3K pathway, activated by TH via TRa/b and the S1 site of avb3, facilitates cell growth and survival and inhibits apoptosis (Chalhoub & Baker 2009).”
BackgroundBergh, J. J., Lin, H.-Y., Lansing, L., Mohamed, S. N., Davis, F. B., Mousa, S., & Davis, P. J. (2005) · Endocrinology · doi:10.1210/en.2005-0102 · Cited by 497
Rapid nongenomic actions of thyroid hormone
Hiroi, Y., Kim, H.-H., Ying, H., Furuya, F., Huang, Z., Simoncini, T., Noma, K., Ueki, K., Nguyen, N.-H., Scanlan, T. S., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0601600103 · Cited by 380 · cited 1×
“Cao et al. (2009) could demonstrate PI3K activation in TRa overexpressing neuronal cells and Hiroi et al. (2006) found TRa1 association with p85a followed by phosphorylation of Akt/PKB, a downstream target of PI3K, and activation of endothelial nitric oxide synthase. avb3 as TR Bergh et al. (2005)…”
BackgroundA Mutation in the Thyroid Hormone Receptor Alpha Gene
Bochukova, E., Schoenmakers, N., Agostini, M., Schoenmakers, E., Rajanayagam, O., Keogh, J. M., Henning, E., Reinemund, J., Gevers, E., Sarri, M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1110296 · Cited by 379 · cited 1×
“The clinical differences between patients with resistance to TH (RTH) due to TRb and TRa mutations further demonstrate that distinct physiological roles for the TR isoforms exist (Refetoff & Dumitrescu 2007, Bochukova et al. 2012, Ferrara et al. 2012, van Mullem et al. 2012).”
BackgroundFactors Related to Inflammation of the Ovarian Epithelium and Risk of Ovarian Cancer
Ness, R. B., Grisso, J. A., Cottreau, C., Klapper, J., Vergona, R., Wheeler, J. E., Morgan, M., & Schlesselman, J. J. (2000) · Epidemiology · doi:10.1097/00001648-200003000-00006 · Cited by 363 · cited 2×
“history of ovarian cancer) (Ness et al. 2000).”
BackgroundInfluentialA Mutation in the Thyroid Hormone Receptor Alpha Gene
Bochukova, E. G., Schoenmakers, N. A., Agostini, M., Schoenmakers, E., Rajanayagam, O., Keogh, J. M., Henning, E., Reinemund, J., Gevers, E. F., Sarri, M., et al. (2012) · UCL Discovery (University College London) · Cited by 327
Research works printed but not linked: 1
- Speranza G Rubinstein L Ivy SP Harris PJ 2011 Correlation between adverse event reports of hypothyroidism and clinical response in patients treated with vascular endothelial growth factor receptor inhibitors (VEGFR-I). Journal of Clinical Oncology29(Supplement: ASCO Meeting Abstracts Part 1) abstract 2602 · doi:10.1200/jco.2011.29.15_suppl.2602
Cited by
de Filette, J., Andreescu, C., Cools, F., Bravenboer, B., & Velkeniers, B. (2019) · Hormone and Metabolic Research · doi:10.1055/a-0843-3366 · Cited by 381
“[134], observations in mouse models suggest that hypothyroidism induced by propylthiouracil suppresses tumor growth, whereas T4 administration had the opposite effect [135, 136].”
BackgroundBelfiore, L., Saunders, D. N., Ranson, M., Thurecht, K. J., Storm, G., & Vine, K. L. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.02.040 · Cited by 294
Thyroid Hormones and Cancer: A Comprehensive Review of Preclinical and Clinical Studies
Krashin, E., Piekiełko-Witkowska, A., Ellis, M., & Ashur-Fabian, O. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00059 · Cited by 217
“A great deal of research has been conducted in recent decades to determine how thyroid hormones exert their growth-promoting effect (7).”
BackgroundJonklaas, J., Bianco, A. C., Cappola, A. R., Celi, F. S., Fliers, E., Heuer, H., McAninch, E. A., Moeller, L. C., Nygaard, B., Sawka, A. M., et al. (2021) · Thyroid® · doi:10.1089/thy.2020.0720 · Cited by 172
“Thyroid dysfunction, mostly hypothyroidism, is an adverse effect of checkpoint inhibitor treatment for cancer, and has been associated with longer survival in these studies (36,37).”
Self-citationHoffman, K., Lorenzo, A., Butt, C. M., Hammel, S. C., Henderson, B. B., Roman, S. A., Scheri, R. P., Stapleton, H. M., & Sosa, J. A. (2017) · Environment International · doi:10.1016/j.envint.2017.06.021 · Cited by 167
“…including thyroid, suggesting that chemicals that disrupt 65 thyroid hormone homeostasis in a significant way could contribute to cancer risk or severity (e.g. 66 Lin et al. 2016; Hellevik et al. 2009; D'Avanzo et al. 2005; Brinton et al. 2007; Søgaard et al 67 2016; Moeller and Führer 2013).”
Background
Metadata
- Authors
- Moeller, L. C., & Führer, D.
- Affiliations
- University of Duisburg-Essen (DE)
- ORCID
- Moeller, Lars C
- Venue
- Endocrine-Related Cancer
- Publisher
- Bioscientifica
- Published
- 2013-04-01
- Volume
- 20
- Issue
- 2
- Pages
- R19-R29
- ISSN
- 1351-0088 (ISSN-L)
- 1479-6821
- OpenAlex
- W2128280017
- Cited by
- 184
- References
- 76
- Citations by year
- 2026: 7 · 2025: 14 · 2024: 16 · 2023: 14 · 2022: 18 · 2021: 18 · 2020: 15 · 2019: 19 · 2018: 13 · 2017: 10 · 2016: 14 · 2015: 18 · 2014: 8
- FWCI
- 1.95
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Endocrine Related Cancer (publishedVersion)
- PubMed (publishedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
- Keywords
- thyroid hormones, thyroid hormone receptor, cancer, hypothyroidism, tumor promotion, phosphatidylinositol 3-kinase, MAPK signaling, angiogenesis, alpha v beta 3 integrin, thyroid-stimulating hormone, colon cancer, lung cancer, prostate cancer, breast cancer, glioblastoma, head and neck cancer, renal cell carcinoma, sunitinib, tyrosine kinase inhibitors, cancer survival, metastasis
- MeSH terms
- Animals, Disease Models, Animal, Humans, Neoplasms, Receptors, Thyroid Hormone, Thyroid Hormones
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Thyroid hormone, thyroid hormone receptors, and cancer: a clinical perspective. https://app.cochat.ai/papers/10.1530/erc-12-0219
- The paper
- Moeller, L. C., & Führer, D. (2013). Thyroid hormone, thyroid hormone receptors, and cancer: a clinical perspective. Endocrine-Related Cancer. https://doi.org/10.1530/erc-12-0219
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.